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Abstract
Background: Because pediatric antineutrophil cytoplasmic antibody-associated vasculitis is rare, management generally
relies on adult data. We assessed treatment practices, uptake of existing clinical assessment tools, and interest in
pediatric treatment protocols among rheumatologists caring for children with granulomatosis with polyangiitis (GPA)
and microscopic polyangiitis (MPA).
Methods: A needs-assessment survey developed by an international working group of pediatric rheumatologists and
two nephrologists was circulated internationally. Data were summarized with descriptive statistics. Pearson’s chi-square
tests were used in inferential univariate analyses.
Results: The 209 respondents from 36 countries had collectively seen ~1600 children with GPA/MPA; 144 had seen
more than two in the preceding 5 years. Standardized and validated clinical assessment tools to score disease severity,
activity, and damage were used by 59, 63, and 36%, respectively; barriers to use included lack of knowledge and limited
perceived utility. Therapy varied significantly: use of rituximab rather than cyclophosphamide was more common among
respondents from the USA (OR = 2.7 [1.3-5.5], p = 0.0190, n = 139), those with >5 years of independent practice experience
(OR = 3.8 [1.3-12.5], p = 0.0279, n = 137), and those who had seen >10 children with GPA/MPA in their careers (OR = 4.39
[2.1-9.1], p = 0.0011, n = 133). Respondents who had treated >10 patients were also more likely to continue maintenance
therapy for at least 24 months (OR = 3.0 [1.4-6.4], p = 0.0161, n = 127). Ninety six percent of respondents believed in a need
for pediatric-specific treatment guidelines; 46% supported adaptation of adult guidelines while 69% favoured guidelines
providing a limited range of treatment options to allow comparison of effectiveness through a registry.
Conclusions: These data provide a rationale for developing pediatric-specific consensus treatment guidelines for GPA/MPA.
While pediatric rheumatologist uptake of existing clinical tools has been limited, guideline uptake may be enhanced if
outcomes of consensus-derived treatment options are evaluated within the framework of an international registry.
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Background
Antineutrophil cytoplasmic antibody- (ANCA-) associ-
ated vasculitis (AAV) describes the subset of vasculitides
primarily involving small vessels: granulomatosis with
polyangiitis (GPA, formerly Wegener’s granulomatosis),
microscopic polyangiitis (MPA), eosinophilic granuloma-
tosis with polyangiitis (EGPA, formerly Churg-Strauss
syndrome), and renal-limited pauci-immune glomerulo-
nephritis [1]. Although rare in childhood, AAV carries a
high burden of morbidity. With the use of high-dose
corticosteroids and cyclophosphamide, AAV is no longer
rapidly fatal in the majority of affected children; how-
ever, these treatments have significant adverse effects.
Balancing the risks associated with existing therapies
against the damage associated with under- or over-
treatment remains a challenge. In adult populations, this
balance has been incrementally fine-tuned through clin-
ical trials that rely on accurate disease sub-classification
and scoring tools to stage disease severity, activity, and
damage (Table 1). The rarity of pediatric AAV has lim-
ited opportunities for pediatric clinical trials such that
management decisions are largely informed by adult data
[2], with potential for significant practice variation.
A 2005 survey of Childhood Arthritis and Rheumatol-
ogy Research Alliance (CARRA) members elicited over-
whelming consensus on the need to study childhood-
onset vasculitis independently from adult disease [3].
ARChiVe (A Registry for Childhood Vasculitis) was
established in 2007 based on this imperative for
pediatric-specific data collection. A concurrent initiative
of the Pediatric Rheumatology European Society (PRES)
also helped generate time-of-diagnosis data to support
the development of pediatric-specific classification cri-
teria and assessment tools. More recently, PedVas
(Pediatric Vasculitis Initiative [4]; https://clinicaltrials.-
gov/ct2/show/NCT02006134) has allowed collection of
clinical data and biological samples to ARChiVe. While
pediatric clinical trials remain difficult, an international
Table 1 Definitions of clinical tools included in survey questions
Clinical tool Description
Birmingham Vasculitis Activity Score (BVAS) Scoring tool designed to document new or
worseningfeatures of clinically
active AAV. Items are categorized into 9 groups
by organ system [11].
BVAS Version 3 2009 update to BVAS [11, 39].
BVAS for Wegener’s Granulomatosis (WG) Modification of BVAS that removes features unlikely
to occur in GPA [13, 40].
Pediatric Vasculitis Activity Score (PVAS) Pediatric version of BVAS preliminarily validated in
children [12].
EUVAS Severity Score Classification system for AAV based on disease extent
and severity. Subgroups
include localized, early systemic, generalized, severe renal,
and refractory disease [41].
Five Factor Score Scoring tool based on factors associated with poor
prognosis: cardiac symptoms,
gastrointestinal involvement, renal insufficiency, proteinuria,
and central nervous
system involvement [42].
Wegener’s Granulomatosis Etanercept
Trial (WGET) Severity Score
Sub-classification based on modified ACR criteria for limited
versus extensive disease [43].
Disease Extent Index (DEI) Tool for scoring disease activity based on organ system, with
distinct domains from those
included in BVAS [44].
Physician’s Global Assessment (PGA) Physician’s global assessment of disease activity on a 10 cm
visual analogue scale.
Vasculitis Damage Index (VDI) Scoring tool used to record damage due to disease or treatment.
Items are categorized
into 11 groups by organ system with binary scoring [14].
Pediatric VDI (PVDI) Pediatric modification of the adult VDI; not yet formally validated
in children [14, 15].
AAV Index of Damage (AVID) Tool for grading disease- or treatment-associated damage, with
weighting of items based
on potential morbidity and mortality [45].
Combined Damage Assessment Index Combination of items from AVID and VDI, divided into 17
organ-based categories [46].
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registry such as ARChiVe might provide the opportunity
to compare effectiveness of a limited range of standard-
ized treatment options and ultimately generate evidence-
based guidelines. This strategy has been pursued for
uvenile dermatomyositis, another rare pediatric rheum-
atic disease [5].
As a first step toward developing treatment guidelines
for pediatric AAV, we sought to better understand the
diversity of beliefs and practices associated with current
care. We conducted an international needs assessment
survey of physicians involved in the diagnosis and man-
agement of children with GPA and MPA, with the fol-
lowing aims: (1) to assess the level of community
experience with pediatric AAV; (2) to assess uptake of
existing classification criteria, clinical scoring tools, and
treatment guidelines; (3) to assess the extent of variation
in current treatment practices; and (4) to determine
interest in and capacity for use of pediatric treatment
protocols.
Methods
A survey draft developed by the Pediatric Rheumatology
group and a nephrologist at British Columbia Children’s
Hospital was finalized with input from the Vasculitis
Working Groups of CARRA and PRES. The survey com-
prised 47 predominantly categorical multi-choice ques-
tions in three sections (Additional file 1). The first
section addressed practice type and experience with
pediatric GPA and MPA (EGPA was excluded given its
rarity in pediatrics). Respondents caring for fewer than
two children with GPA and/or MPA over the past 5
years were then given the option to exit. The second
section queried use and knowledge of classification cri-
teria and formal scoring tools for disease severity, activ-
ity and damage (Table 1). Practitioners were also asked
about their use of adult treatment guidelines and per-
ceived need for pediatric-specific guidelines. The third
section queried motivations for and barriers to participa-
tion in clinical registries. Levels of assigned value were
requested using a five-point Likert scale from 1 (not im-
portant) to 5 (extremely important).
Members of CARRA, the Canadian Alliance of
Pediatric Rheumatology Investigators (CAPRI), the Aus-
tralian Pediatric Rheumatology Group, the PRES-
CARRA Vasculitis Working Group, and the Pediatric
Rheumatology Bulletin Board (ped-rhe-list@mcmas-
ter.ca) were invited by email to complete the web-based
survey (estimated 500 personal email invitations). The
survey was administered using REDCap electronic data
capture tools [6] hosted at the University of British
Columbia (UBC) from July 24 to September 29, 2015.
The survey was conducted as a quality assurance initia-
tive for PedVas, which was approved by the Children’s
and Women’s Research Ethics Board of UBC (H12-
00894). Under Article 2.5 of the Tri Council Policy
Statement, quality assurance/improvement activities are
not subject to further institutional review.
Descriptive statistics were used to quantify response
frequencies and means. Unless otherwise specified, fre-
quencies are reported relative to the total number of re-
spondents completing each question. Odds ratios (OR)
were determined as measures of association. Limits of
95% confidence intervals of OR are reported in square
brackets. Inferential univariate analysis with two-sided
Pearson’s chi-square tests and Benjamini-Hochberg cor-
rection for multiple comparisons was used to test 11 hy-
potheses with a false discovery rate of 5% [7]. Corrected
p-values are reported. Analysis was performed using
Microsoft Excel Version 14.6.7 and Prism Version 5.0a
(GraphPad Software Inc., La Jolla, CA).
Results
Respondent characteristics
Of 216 respondents opening the survey, 209 completed it,
yielding an estimated response rate of approximately 40%.
Sixty-five (31%) chose to exit as they had not cared for two
or more patients with GPA/MPA in the preceding 5 years.
The 144 respondents completing the full survey practiced
in 36 countries, predominantly the USA (48%), with others
from Canada (13%), Italy (4%), Australia (3%), Germany
(4%), Turkey (4%), United Kingdom (4%), Brazil (2%), and
Sweden (2%). Most respondents (92%) belonged to one or
more national or international rheumatology organizations,
including CARRA (56%), PRES (32%), CAPRI (10%), the
PRES-CARRAVasculitis Working Group (10%), and others
(18%). Approximately half of respondents had practiced for
less than 10 years after formal training (21% for less than 5
years and 26% for 5-10 years); among the rest, 20% each
had practiced for 10-20 and 20-30 years and 10% for 30-
40 years. The combined lifetime experience of respondents
was at least 1600 patients with GPA/MPA (some shared):
47% had seen fewer than ten patients, 39% had seen 10-20,
and only 14% had seen more than 20. The majority of re-
spondents (61%) had seen five or fewer patients with a new
diagnosis of GPA or MPA within the past 5 years (mode 3,
median 5, IQR 3-8 patients).
Most respondents belonged to group practices, sharing
diagnostic and treatment decisions for all patients (46%)
or managing patients independently while sharing on-
call responsibilities (41%). A minority worked in a solo
practice (7%) or in another practice arrangement (6%),
predominantly hospital-based. For patients who had also
been assessed by a nephrologist, the majority of respon-
dents reported making collaborative treatment decisions,
30% in a combined nephrology/rheumatology clinic and
37% in separate clinic settings. Some reported variation
in the responsible subspecialty depending on factors
such as who had seen the patient first (18%), while 13
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and 2% of respondents reported independent manage-
ment by rheumatology or nephrology, respectively.
Classification criteria
There were between 129 and 144 responses (89-100%)
to subsequent individual questions regarding diagnosis
and management. While the majority (73%) reported
that they always sub-classify AAV as either GPA or
MPA, 26% endorsed only sometimes sub-classifying.
Table 2 shows the number of respondents familiar with
– and using – existing criteria for defining or classifying
AAV. Most were familiar with ACR1990 [8] and
EULAR/PRINTO/PRES 2008 [9] classification criteria
for GPA, and with CHCC 1994 disease definitions [10].
Serology (cANCA/PR3 versus pANCA/MPO) and
EULAR/PRINTO/PRES 2008 criteria [9] were most fre-
quently used for distinguishing between GPA and MPA
in clinical practice. Notably, 66% of all respondents
reported using more than one set of criteria, and those
using informal methods considered histopathology, anti-
body status, and specific organ involvement. The rationale
for sub-classification was predominantly prognostication
(73%), influence on treatment choice (48%), involvement
in clinical studies/trials (39%), and access to treatments
(29%). All respondents felt that distinguishing between
GPA and MPA was at least somewhat important for
research (mode 4, median 4, IQR 3-4).
Disease severity, activity, and damage
The proportions of respondents using formal tools to as-
sess disease severity, activity, and damage are shown in
Table 3. While most respondents used formal assess-
ment tools for severity (59%) and activity (63%), only
36% had ever formally assessed disease damage. The Bir-
mingham Vasculitis Activity Score (BVAS) [11], the
Pediatric Vasculitis Activity Score (PVAS) [12], and
BVAS for Wegener’s Granulomatosis [13] – tools
designed primarily for assessment of disease activity –
were frequently used to stage severity, but tools such as
the Five Factor Score and the EUVAS and WGET sever-
ity scores were used by a minority. PVAS, BVAS, and
physician’s global assessment on a 10 cm visual analogue
scale (PGA) were the primary tools used by respondents
for scoring disease activity, typically at the time of diag-
nosis: 39% at only some follow-up visits, 33% at all visits,
16% at prescribed times according to research protocols,
and 7% at the time of diagnosis only. Most respondents
felt formal assessment of disease activity was somewhat
important to clinical management (mode 3, median 5,
IQR 3-4), and more important to research (mode 5, me-
dian 5, IQR 4-5). Most commonly used tools for scoring
disease damage include the Vasculitis Damage Index
(VDI) [14] or its pediatric adaptation, PVDI [15]. Similar
to scoring of disease activity, respondents assessed dis-
ease damage primarily at the time of diagnosis: 35% at
only some follow-up visits, 23% at prescribed times only,
and 31% at every visit. Respondent rationales for not
Table 2 Familiarity with and use of vasculitis classification criteria
and disease definitions to differentiate GPA from MPA in childrena
Criteria Familiar (%) Using (%)
EULAR/PRINTO/PRES
2008 criteria [9]
78 57
ANCA (PR3/MPO) NDb 57
ACR 1990 criteria [8, 19] 72 29
CHCC 1994 [10] 62 32
CHCC 2012 [1] 47
EMA classification
algorithm (2007) [22]
18 5
Pediatric Modification of EMA
classification algorithm (2012) [21]
Informal criteria NDb 19
Other formal criteria NDb 1
aData represent percentage of respondents out of n = 144 (familiar) or
n = 143 (using)
bNo data
Table 3 Use of formal disease severity, activity, and damage
scoring tools by survey respondents in the assessment of children
with GPA or MPAa
Parameter Scoring tool Respondents (%)
Severityb PVAS [12] 41
BVAS [11] 20
BVAS for WG [13] 19
EUVAS Severity Score [41] 11
Five Factor Score [42] 8
WGET Severity Score [43] 7
Disease Extent Index [44] 1
Other 1
Never formally assess 41
Activityc PVAS [12] 38
Physician’s Global Assessment 29
BVAS [11] 19
BVAS for WG [13] 13
BVAS version 3 [39] 6
Other tool 0
Never formally assess 37
Damagec Pediatric VDI [15] 31
VDI [14] 10
AAV Index of Damage [45] 3
Combined Damage Assessment
Index [46]
1
Other 0
Never formally assess 64
aData represent percentage of respondents out of bn = 142, cn = 141
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using formal assessment tools are shown in Table 4 and
included use of histopathology, lack of effect on manage-
ment, lack of familiarity, and inconvenience.
Treatment guidelines
A majority of respondents (53%) reported using a com-
bination of resources to guide treatment decisions, most
commonly EULAR/EUVAS recommendations (24%). A
minority used site-specific standardized protocols (7%);
others used pediatric textbook recommendations (4%),
individualized approaches according to personal inter-
pretation (4%), or advice from colleagues (6%). The ma-
jority of respondents (96%) believed in a need for
pediatric treatment guidelines for GPA/MPA. Over half
(58%) were interested in being involved in the process of
consensus guideline development – 43% through an it-
erative survey – while others felt they did not have the
time (13%) or relevant expertise (19%), or were unsure
(9%). There was no association between group member-
ship and the desire to participate in guideline develop-
ment (OR = 1.4 [0.4, 5.1], p = 0.7206, n = 131), although
respondents practicing outside the USA and Canada
were more likely to want to participate than those within
(OR = 4.2 [1.9, 9.0], p = 0.0011, n = 135). Most respon-
dents supported consensus guidelines drafted by an
expert group (69%) and believed in the need for a lim-
ited range of options to allow for comparative outcome
assessment through a clinical registry (63%). Slightly less
than half (46%) felt modification of recommendations
for adult disease was an acceptable method for generat-
ing pediatric treatment guidelines.
Treatment practices
All respondents followed a remission-induction and
remission-maintenance model, switching from induction
to maintenance therapy within 3-6 months. In adult
studies, choice of induction agent may be adjusted based
on measures of disease severity, primarily to limit use of
aggressive life-saving treatment – specifically cyclophos-
phamide – that also has significant toxicity and may be
unwarranted in milder disease. Two-thirds (67%) of re-
spondents endorsed always using more aggressive treat-
ment for patients with severe disease, while 32%
reported only sometimes choosing induction therapy
based on disease severity. Table 5 shows first-line induc-
tion and maintenance therapies preferred by respon-
dents for treatment of AAV; respondents were not asked
to distinguish between GPA- and MPA-specific regi-
mens. In patients with severe disease not requiring in-
tensive care, cyclophosphamide (CYC) was the first
choice of remission-induction agent by 66% of respon-
dents, while 31% stated they would choose rituximab
(RTX). Use of RTX rather than CYC as an induction
agent was more frequently reported by respondents from
the USA (OR = 2.7 [1.3, 5.5], p = 0.0190, n = 139), those
with greater than 5 years of experience (OR = 3.8 [1.3,
12.5], p = 0.0279, n = 137), and those who had seen
more than 10 patients with GPA/MPA in their careers
(OR = 4.39 [2.1, 9.1], p = 0.0011, n = 133).
Figure 1 shows the heterogeneity among prescribing
practices for both CYC and RTX. Most respondents
used CYC for induction until clinically inactive disease
up to a maximum of 6 months (69%), while 16% treated
Table 4 Reported rationales against use of formal assessment
tools for scoring disease severity, activity, and damage in the
assessment of children with GPA or MPAa
Parameter Rationale against use of tool Respondents (%)
Severityb Use of histopathological findings 53
No effect on management 34
Lack of familiarity with tools 26
No value added beyond clinical judgment 24
Inconvenience 16
Other 5.3
Activityc Lack of familiarity with tools 47
Inconvenience 43
No effect on management 22
Lack of applicability of tools for adults 20
No value added beyond clinical judgment 18
Damaged Lack of familiarity with tools 58
Inconvenience 32
Lack of applicability of tools for adults 20
No effect on management 18
No value added beyond clinical judgment 12
aData represent percentage of respondents out of bn = 38, cn = 51, dn = 91
Table 5 Induction and maintenance agents used by
respondentsa
Indication Agent Respondents
(%)
Induction agent in severe diseaseb Cyclophosphamide 66
Rituximab 31
Other 2
Induction agent if not using CYC
or RTX (e.g. for less severe disease)c
Methotrexate 40
Azathioprine 30
Mycophenolate 25
Other 4
Maintenance therapyd Azathioprine 45
Methotrexate 23
Mycophenolate 18
Rituximab 11
Other 3
aData represent percentage of respondents out of bn = 140, cn = 138, dn = 141
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for a defined duration between 3 and 7 months, 7% gave
only 1-2 IV doses in conjunction with RTX, 5% contin-
ued induction therapy until clinical inactivity regardless
of duration, and 2% employed some other regimen. The
most common first choice of induction therapy in chil-
dren not receiving CYC or RTX was methotrexate
(MTX), followed by azathioprine (AZA) and mycophe-
nolate mofetil (MMF) (Table 5).
The most commonly used remission-maintenance
treatment was AZA, followed by MTX, MMF, and RTX
(Table 5). There was no association between mainten-
ance therapy and practice location (Canada vs. USA vs.
other; p = 0.2009, n = 139), years of practice (<5 vs. 5 or
more; p = 0.3042, n = 141), or total number of patients
seen with GPA/MPA (<10 vs. 10 patients or more;
p = 0.8328, n = 141). The provisional choice for main-
tenance therapy duration of 24 (46%), 18 (19%), 36
(14%), or 12 (13%) months was associated with total pa-
tient experience: 75% of respondents who had seen more
than 10 GPA/MPA patients in their careers planned for
at least 24 months of therapy, compared to 52% of those
who had seen fewer than 10 patients (OR = 3.0 [1.4,
6.4], p = 0.0161, n = 127). Duration of maintenance ther-
apy was not associated with practice location (Canada
vs. USA vs. other; p = 0.3110, n = 130) or years of prac-
tice (<5 vs. 5 or more; OR = 1.6 [0.70, 3.89], p = 0.3109,
n = 127). Concurrent corticosteroid duration initiated at
induction was typically six (39%) or 12 (40%) months,
with some respondents continuing for 18 (6%), 24 (4%),
or 36 (0.7%) months and 11% chose variable periods ac-
cording to disease severity. 93% of respondents routinely
recommended plasma exchange in certain situations:
severe pulmonary hemorrhage and/or rapidly progres-
sive renal disease (76%), rapidly progressive renal disease
only (8%), pulmonary hemorrhage only (5%), and with
co-existent conditions (10%).
Interest in clinical registries
All respondents felt that an international collaborative
registry was important for comparative outcome assess-
ment of treatment strategies for GPA/MPA, with 64% of
respondents selecting “very important” (mode 5, median
5, IQR 4-5). Primary motivations for participation in
clinical studies or collaborative registries included the
potential to improve outcomes for children with AAV
(91%), access to available tools and resources (58%), en-
dorsement by a formal network of investigators (49%),
potential publication authorship (46%), and association
with specific research objectives (40%). Only 15% of re-
spondents felt that a monetary stipend was a major mo-
tivation. Registry-associated resources believed to be of
most value included an automated PVAS calculator
(82%), an online algorithm to stage disease severity with
links to corresponding treatment guidelines (68%), an
automated PVDI calculator (66%), a classification tool
based on entered patient data (54%), and a printable
table to track patient data over multiple visits (54%).
Most clinicians had resources available to assist with the
use of registry data entry and clinical tools, including
computer and internet access in the clinic (80% each)
and a trainee or fellow (58%). Fewer had a research as-
sistant (47%), support for review board applications
(37%), technology support (33%), or a research nurse
(23%). Major barriers to registry participation included
Fig. 1 Typical dosing regimens prescribed for cyclophosphamide (CYC) and rituximab (RTX) induction therapy. Data represent number of
respondents out of n = 140 for both agents. aEUVAS protocol
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insufficient support for data entry (59%), lack of time
(43%), burden of ethics review board approval (32%),
and lack of patients (24%).
Discussion
This survey emphasizes the limited individual experience
among clinicians caring for children with GPA and MPA
and reiterates clinicians’ aspirations to study childhood-
onset vasculitis independently from adult disease [3].
International collaborations within the last decade have
facilitated the development of pediatric-specific classifi-
cation criteria for GPA [9] and scoring tools for disease
activity and damage [12, 15]. They have also evaluated
the pediatric utility of adult patient algorithms for classi-
fying MPA [16] and staging disease severity [17]. More-
over, the recent revision of the CHCC definitions is
relevant to both adults and children [1]. These newly
developed criteria, definitions, and clinical tools are es-
sential for systematic evaluation of drug efficacy. How-
ever, the present survey reveals limited uptake by
pediatric caregivers and identifies several challenges in
the development, implementation, and evaluation of
pediatric treatment guidelines.
Distinguishing GPA from MPA
Most respondents believed that the distinction between
GPA and MPA in patients with AAV was important for
prognostication, consistent with meta-analyses of adult
studies showing lower 5-year survival in MPA versus
GPA [18] and of pediatric studies showing less frequent
relapses [18] and more severe renal disease [16] in MPA.
While respondents were familiar with both the ACR
1990 criteria for GPA [9] and its EULAR/PRINTO/PRES
2008 pediatric adaptation, neither organization includes
criteria to define MPA [8, 19]. Not surprisingly, respon-
dents often used multiple methods to differentiate (sub-
classify) GPA and MPA phenotypes, and 25% reported
sometimes not differentiating. Frequently, ANCA speci-
ficity to PR3 or MPO was used “erroneously” as the
primary differentiating criterion to define GPA and
MPA, respectively. Adult studies suggest that genetics,
pathophysiology, and clinical outcomes may be more
strongly associated with antibody status than with the
clinical syndromes [20]; although the populations de-
fined by PR3 or MPO antibodies overlap with GPA and
MPA, respectively, they are not the same. Indeed, most
respondents were not aware of the recently revised
CHCC 2012 definitions that do not incorporate ANCA
specificity but arguably provide the clearest discriminat-
ing definitions of GPA and MPA [1]. Moreover, less than
20% of respondents were familiar with the European
Medicines Agency (EMA) classification algorithm or its
pediatric modification [21, 22]. However, this is a com-
plicated tool primarily used in the research setting.
Clinical scoring tools
Multiple national and international rheumatology organiza-
tions have published treatment guidelines for management
of AAV in adults [23–31]. Many require formal clinical
measurement tools to assess disease “severity” (to stratify ap-
propriate therapy) and “activity” (to determine when to start,
stop, or modify therapy). These standardized measures also
guide entry of adult patients into research studies and will
inevitably guide research eligibility in children. However,
one third of respondents reported only sometimes tailoring
induction therapy to a formalized disease severity scale, sug-
gesting that other factors – likely including informal assess-
ment, histopathology [32], and specific organ involvement –
influence management decisions. In children, PVAS [12]
may show better correlation with treatment decisions than
the BVAS v.3 [33]; nevertheless, equal proportions of re-
spondents used BVAS or its variants. Furthermore, evalu-
ation of permanent damage from disease or treatment is
required for outcome assessment and may allow prediction
of mortality [34]. The PVDI is a relatively recent pediatric
modification of the adult VDI [14] yet to be validated [15];
however, few respondents used either tool. Lack of know-
ledge or familiarity – as well as perceived lack of utility –
may account for some lack of uptake. Successful implemen-
tation of practice guidelines requiring standardized assess-
ment tools will depend on improved clinician engagement,
clear clinical utility, and feasibility of use.
Treatment practices
Consistent with guidelines for treatment of adults with
AAV, all survey respondents employed a remission-
induction and remission-maintenance model. Although
25% of respondents used EULAR/EUVAS recommenda-
tions to guide their treatment decisions, many employed
a combination of resources. There was significant vari-
ation in medication and dosing regimens for childhood
GPA/MPA, with variable use of evidence-based recom-
mendations from existing adult guidelines.
Potential engagement in comparative effectiveness
research
An overwhelming majority of respondents believed in the
need for pediatric-specific treatment guidelines and sup-
ported guideline development by expert group consensus. It
is not simple to reconcile these aspirations with the limited
uptake of recent pediatric-specific research and consensus
reports, although the described lack of knowledge or famil-
iarity – as well as unclear added benefit beyond current
practice – likely contribute. In view of the high frequency of
renal disease (75%) among pediatric AAV patients [16] and
the existing high level of cross-specialty collaboration, future
efforts towards developing and implementing guidelines for
managing patients with AAV must further engage pediatric
nephrologists.
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A recent European initiative to develop standards of
care for pediatric rheumatic diseases, SHARE (Single Hub
and Access point for Paediatric Rheumatology in Europe)
[35], will soon provide consensus-based guidelines for
management of pediatric vasculitides, including GPA [36].
While many of these recommendations will be based on
adult data, most survey respondents favored longer-term
comparative outcome assessment of a range of possible
consensus approaches. Given barriers to uptake of existing
pediatric-specific tools – many of which will be part of
standardized guidelines – incentives for implementation
are critical. A registry that provides treatment guidelines
endorsed by national/international rheumatology organi-
zations, access to clinical tools with automated scoring
calculators, and individual patient summary progress re-
ports might further improve engagement and uptake.
Limitations of this study include a sample population
that likely underestimates true variability in practice
given the selection bias associated with elective survey
completion [37] and response rates below 50% [38]. Par-
ticipants were reached through formal organizations and
therefore may represent a particularly informed group,
leading to overestimation of the use of clinical tools and
guidelines. Moreover, the survey included few respon-
dents outside Europe and North America, and therefore
is limited in generalizability particularly with respect to
practice variation in Asian and African countries.
Conclusions
Taken together, these data suggest a need for and interest
in consensus treatment guidelines for pediatric GPA and
MPA. They also point to potential challenges associated
with guideline development and implementation. Under-
standing the barriers to uptake of existing classification
criteria and formal assessment tools will inform efforts to
improve standardization of classification and assessment
to guide therapy. Physicians’ aspirations for pediatric-
specific, evidence-based treatments may motivate uptake
of guidelines that evolve from this needs assessment sur-
vey and, imminently, from SHARE. Consensus-derived
guidelines that include a range of specific treatment op-
tions – if provided together with mechanisms for com-
parative effectiveness research through an international
registry – may facilitate clinician engagement and ultim-
ately lead to improved outcomes for children with AAV.
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